Primary tumor burden

"Primary tumor burden" is **not a molecular target, receptor, enzyme, or protein**. Instead, it is a clinical and pathological concept referring to the **amount of cancer present in the primary tumor**, often quantified by measures such as the size of the primary lesion, number of lesions, or total volume[5][1][2]. In oncology practice and research, "tumor burden" may also include metastatic sites and overall disease extent. It is used as a prognostic factor in various cancers—higher primary tumor burden generally correlates with worse outcomes and can influence treatment decisions[1][2][4]. However, it does not represent a discrete molecule or druggable entity; rather, it is an aggregate measure used for risk stratification and therapy planning. There are no drugs that directly "target" primary tumor burden itself; instead, therapies aim to reduce overall cancer mass through cytotoxicity or other mechanisms. Biomarkers like LDH levels and TMB may be associated with high tumor burdens but do not define them[2][6]. Because "primary tumor burden" refers to a measurement/clinical parameter rather than a specific molecular entity or therapeutic target class (such as receptor or enzyme), this entry should be flagged as incorrect for structured drug-target databases.

Other names

Tumor burdenTumor loadHigh tumor burden (HTB)Primary lesion tumor burden